Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
$56.66
$1.93(2.32%)
At close: 4:00 PM EST
$56.66
$1.93(2.32%)
Day’s Range― - ―
52-Week Range$45.05 - $119.07
Previous CloseN/A
Volume3.65M
Average Volume (3M)14.28M
Market Cap
$257.99B
Enterprise Value$319.55B
Total Cash (Recent Filing)$18.93B
Total Debt (Recent Filing)$99.27B
Price to Earnings (P/E)15.8
Beta1.15
Next Earnings
Nov 05, 2025EPS Estimate
0.78Last Dividend Ex-Date
Aug 18, 2025Dividend Yield3.26%
Share Statistics
EPS (TTM)0.93
Shares Outstanding3,390,128,000
10 Day Avg. Volume13,723,715
30 Day Avg. Volume14,282,643
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)19.23
Price to Sales (P/S)9.50
P/FCF Ratio39.62
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.22
Enterprise Value/Ebitda1.87
Forecast
1Y Price Target
$60.73Price Target Upside7.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesNovo becomes the preferred choice for obesity treatment, with a significant upside potential in stock price.
Regulatory AchievementsThe FDA's publication of a GLP-1 API 'Green List' is a mild regulatory win for Novo.
Strategic RestructuringNovo's restructuring and strategy shift under CEO Mike Doustdar is seen as a decisive move.
Bears Say
Market CompetitionNovo Nordisk shares will remain less competitive vs. other peers in the cardiometabolic market.
Market Share PressureLilly's Mounjaro & Zepbound are expected to continue taking incremental U.S. share from Ozempic and Wegovy.
Product ChallengesCompounded semaglutide remains a problem for Novo, despite efforts to address it slowly.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $45.05 and its highest was $119.07 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $257.99B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 20 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 06, 2025. The company reported $0.929 earnings per share for the quarter, beating the consensus estimate of $0.919 by $0.01.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.584 which represents an annual dividend yield of 3.26%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.78.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.929 in its last earnings report, beating expectations of $0.919. Following the earnings report the stock price went down -3.906%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.73 (7.18% Upside)
$60.73 (7.18% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 431.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.75%
12-Months-Change
Fundamentals
Return on Equity
75.95%
Trailing 12-Months
Asset Growth
42.90%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk is a global healthcare company headquartered in Denmark, specializing in the development and manufacturing of pharmaceuticals for diabetes care, obesity management, and other chronic diseases. Established in 1923, the company operates primarily in the biopharmaceutical sector, focusing on insulin and GLP-1 receptor agonists for diabetes treatment, as well as hormone replacement therapy and treatments for hemophilia and growth disorders. Novo Nordisk is recognized for its commitment to innovation and sustainability within the healthcare industry.
NVO Company Deck
NVO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Novo Nordisk reported strong sales and profit growth in the first half of 2025, with significant expansion in obesity care and international operations. However, the company lowered its full-year outlook due to challenges in the U.S. market and decreased free cash flow, reflecting both positive achievements and areas of concern.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$60.73
▲(7.18% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.46% Mutual Funds
0.07% Other Institutional Investors
98.33% Public Companies and Individual Investors